Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, Extranodal NK-T-Cell 1Leukemia, Lymphocytic, Chronic, B-Cell 1Enteropathy-Associated T-Cell Lymphoma 1

Interventions

Cyclophosphamide 11Doxorubicin 9Vincristine 8Methotrexate 6nelarabine 5Prednisone 5Peripheral Blood Stem Cell Transplantation 5Leucovorin 5Cytarabine 5tanespimycin 4merphos 4fludarabine phosphate 4dexamethasone acetate 4dexamethasone 21-phosphate 4auricularum 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Etoposide 4Dexamethasone 4Cyclosporine 4Calcium Dobesilate 4Bortezomib 4prednylidene 3pegaspargase 3deltacortene 3azathiopurine 3Vorinostat 3Thioguanine 3Radiotherapy 3Pharmacogenomic Testing 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Precursor T-Cell Lymphoblastic Leukemia-Lymphoma × duvelisib × Clear all
NCT04639843 2022-11-04

Doxorubicin, CC-(486) (5-azacitidine), Romidepsin, and Duvelisib (hARD) for T-cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Withdrawn
LymphoidOther hematologic neoplasm

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡